Latest Quarterly Report
Filed: 2026-05-14
Key Insights
- The filing is dated May 14, 2026 for Q1 2026 (ended March 31, 2026), indicating Autolus Therapeutics is a clinical-stage or commercial-stage biopharmaceutical company with active operations and reporting requirements.
- The presence of multiple share classes (Ordinary Shares, Deferred Shares, Class B and Class C Deferred Shares) and ADR members suggests a dual-listing structure, likely London and US exchanges, with complex capital structure that may impact shareholder voting and economic rights.
- Detailed tracking of stock-based compensation instruments (RSUs, employee stock options, warrants) across multiple periods indicates significant equity dilution from employee compensation programs, which warrants monitoring for impact on share count and EPS.
- The financial instruments disclosed (money market funds, commercial paper, corporate debt, US Treasury securities, foreign government debt) suggest the company maintains substantial cash reserves, though the actual cash balance and burn rate are not visible in the provided metadata.